0495743 - ÚI 2019 NZ eng J - Článek v odborném periodiku
Svobodová, Š. - Karlíková, M. - Topolčan, O. - Pecen, Ladislav - Peštová, M. - Kott, O. - Treska, V. - Slouka, D. - Kučera, R.
PIVKA-II as a Potential New Biomarker for Hepatocellular Carcinoma – A Pilot Study.
In Vivo. Roč. 32, č. 6 (2018), s. 1551-1554. ISSN 0258-851X. E-ISSN 1791-7549
Klíčová slova: AFP * PIVKA-II * biomarkers * hepatocellular carcinoma * predictive
Impakt faktor: 1.609, rok: 2018 ; AIS: 0.276, rok: 2018
DOI: https://doi.org/10.21873/invivo.11413

Aim: The aim of this study was to evaluate the clinical contribution of protein induced by vitamin K absence (PIVKA-II) for hepatocellular carcinoma (HCC) diagnostics and compare it with alpha-foetoprotein (AFP), a routinely used tumour marker. Materials and Methods: A total of 332 participants were enrolled in this study: 64 with HCC, 48 with liver metastases of colorectal cancer origin, 42 with liver cirrhosis and 178 healthy individuals. Serum levels of PIVKA-II were measured using the chemiluminescent assay of the Architect 1000i System (Abbott, USA) and AFP levels using the chemiluminescent assay by DxI 800 (Beckman Coulter, USA). Results: PIVKA-II achieved better clinical sensitivity than AFP and the difference in this sensitivity was statistically significant. PIVKA-II achieved the best sensitivity (96.9%) in distinguishing between the HCC and control groups with the proposed cut-off value of 60 mAU/ml. Conclusion: Our recommendation is for addition of PIVKA-II to the routine panel of HCC tumour markers.
Trvalý link: http://hdl.handle.net/11104/0288667